InnoCare Pharma's self-developed CDH17-targeting ADC innovative drug ICP-B208 has been approved for clinical trials
InnoCare Pharma (SSE code: 688428; HKEX code: 09969) announced that its self-developed novel ADC drug ICP-B208 targeting CDH17 has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to conduct clinical research.
CDH17 belongs to the cadherin family and plays a key role in tumor cell proliferation, migration, and metastasis. It is highly expressed specifically in various gastrointestinal solid tumors such as colorectal cancer, gastric cancer, pancreatic cancer, and biliary tract cancer, making it one of the most promising emerging targets in the global ADC field. Currently, there are no CDH17-targeting ADC drugs on the market worldwide.
ICP-B208 was developed based on InnoCare Pharma’s self-developed ADC technology platform, utilizing a unique hydrophilic linker paired with a highly active payload, conjugated with a humanized anti-CDH17 antibody. Preclinical studies have shown that ICP-B208 exhibits potent anti-tumor activity even in tumors with low CDH17 expression.
Leveraging its platform's differentiated technological advantages, InnoCare Pharma is simultaneously advancing several innovative ADC drugs that exhibit both potent tumor-killing activity and safety. The novel ADC drug ICP-B794 targeting B7-H3 has entered clinical trials first, while ICP-B208 is the second self-developed ADC innovative drug approved for clinical trials by InnoCare Pharma.
Dr. Jisong Cui, co-founder, chairman, and CEO of InnoCare Pharma, stated: 'The approval of ICP-B208 for clinical trials marks another significant advancement for the company in the field of solid tumor treatment, fully demonstrating the expansion potential of our ADC platform. Going forward, we will continue to accelerate the development of innovative ADC drugs and further enrich our pipeline for solid tumor treatments, bringing more and better innovative treatment options to cancer patients worldwide.'
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Comments
to post a comment